Funding for this research was provided by:
Text and Data Mining valid from 2019-10-30
First Online: 30 October 2019
Compliance with Ethical Standards
: This article was funded by Novo Nordisk. Hanne Haahr is an employee and shareholder of Novo Nordisk. Tim Heise is shareholder of Profil, which has received research funds from Adocia, Boehringer Ingelheim, Dance Pharmaceuticals, Eli Lilly, Gan & Lee Pharmaceuticals, Johnson & Johnson, Mars, MedImmune, Mylan, Nordic Bioscience, Novo Nordisk, Pfizer, Poxel, Saniona, Sanofi, Wockhardt and Zealand Pharma. In addition, Tim Heise is member of advisory panels for Mylan and Novo Nordisk and received speaker honoraria and travel grants from Eli Lilly and Novo Nordisk.